Health-related quality of life in children with sickle cell anemia: Impact of blood transfusion therapy

Lauren M. Beverung*, John J. Strouse, Monica L. Hulbert, Kathleen Neville, Robert I Liem, Baba Inusa, Beng Fuh, Allison King, Emily Riehm Meier, James Casella, Michael R. Debaun, Julie A. Panepinto

*Corresponding author for this work

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The completion of the Multicenter Silent Infarct Transfusion Trial demonstrated that children with pre-existing silent cerebral infarct and sickle cell anemia (SCA) who received regular blood transfusion therapy had a 58% relative risk reduction of infarct recurrence when compared to observation. However, the total benefit of blood transfusion therapy, as assessed by the parents, was not measured against the burden of monthly blood transfusion therapy. In this planned ancillary study, we tested the hypothesis that a patient centered outcome, health-related quality of life (HRQL), would be greater in participants randomly assigned to the blood transfusion therapy group than the observation group. A total of 89% (175 of 196) of the randomly allocated participants had evaluable entry and exit HRQL evaluations. The increase in Change in Health, measured as the child's health being better, was significantly greater for the transfusion group than the observation group (difference estimate = -0.54, P ≤ 0.001). This study provides the first evidence that children with SCA who received regular blood transfusion therapy felt better and had better overall HRQL than those who did not receive transfusion therapy.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalAmerican Journal of Hematology
Volume90
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Sickle Cell Anemia
Blood Transfusion
Quality of Life
Observation
Therapeutics
Risk Reduction Behavior
Group Psychotherapy
Parents
Recurrence
Health

ASJC Scopus subject areas

  • Hematology

Cite this

Beverung, L. M., Strouse, J. J., Hulbert, M. L., Neville, K., Liem, R. I., Inusa, B., ... Panepinto, J. A. (2015). Health-related quality of life in children with sickle cell anemia: Impact of blood transfusion therapy. American Journal of Hematology, 90(2), 139-143. https://doi.org/10.1002/ajh.23877
Beverung, Lauren M. ; Strouse, John J. ; Hulbert, Monica L. ; Neville, Kathleen ; Liem, Robert I ; Inusa, Baba ; Fuh, Beng ; King, Allison ; Meier, Emily Riehm ; Casella, James ; Debaun, Michael R. ; Panepinto, Julie A. / Health-related quality of life in children with sickle cell anemia : Impact of blood transfusion therapy. In: American Journal of Hematology. 2015 ; Vol. 90, No. 2. pp. 139-143.
@article{8cd2162d3e38497388e2e2a7009f5d45,
title = "Health-related quality of life in children with sickle cell anemia: Impact of blood transfusion therapy",
abstract = "The completion of the Multicenter Silent Infarct Transfusion Trial demonstrated that children with pre-existing silent cerebral infarct and sickle cell anemia (SCA) who received regular blood transfusion therapy had a 58{\%} relative risk reduction of infarct recurrence when compared to observation. However, the total benefit of blood transfusion therapy, as assessed by the parents, was not measured against the burden of monthly blood transfusion therapy. In this planned ancillary study, we tested the hypothesis that a patient centered outcome, health-related quality of life (HRQL), would be greater in participants randomly assigned to the blood transfusion therapy group than the observation group. A total of 89{\%} (175 of 196) of the randomly allocated participants had evaluable entry and exit HRQL evaluations. The increase in Change in Health, measured as the child's health being better, was significantly greater for the transfusion group than the observation group (difference estimate = -0.54, P ≤ 0.001). This study provides the first evidence that children with SCA who received regular blood transfusion therapy felt better and had better overall HRQL than those who did not receive transfusion therapy.",
author = "Beverung, {Lauren M.} and Strouse, {John J.} and Hulbert, {Monica L.} and Kathleen Neville and Liem, {Robert I} and Baba Inusa and Beng Fuh and Allison King and Meier, {Emily Riehm} and James Casella and Debaun, {Michael R.} and Panepinto, {Julie A.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/ajh.23877",
language = "English (US)",
volume = "90",
pages = "139--143",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Beverung, LM, Strouse, JJ, Hulbert, ML, Neville, K, Liem, RI, Inusa, B, Fuh, B, King, A, Meier, ER, Casella, J, Debaun, MR & Panepinto, JA 2015, 'Health-related quality of life in children with sickle cell anemia: Impact of blood transfusion therapy', American Journal of Hematology, vol. 90, no. 2, pp. 139-143. https://doi.org/10.1002/ajh.23877

Health-related quality of life in children with sickle cell anemia : Impact of blood transfusion therapy. / Beverung, Lauren M.; Strouse, John J.; Hulbert, Monica L.; Neville, Kathleen; Liem, Robert I; Inusa, Baba; Fuh, Beng; King, Allison; Meier, Emily Riehm; Casella, James; Debaun, Michael R.; Panepinto, Julie A.

In: American Journal of Hematology, Vol. 90, No. 2, 01.02.2015, p. 139-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Health-related quality of life in children with sickle cell anemia

T2 - Impact of blood transfusion therapy

AU - Beverung, Lauren M.

AU - Strouse, John J.

AU - Hulbert, Monica L.

AU - Neville, Kathleen

AU - Liem, Robert I

AU - Inusa, Baba

AU - Fuh, Beng

AU - King, Allison

AU - Meier, Emily Riehm

AU - Casella, James

AU - Debaun, Michael R.

AU - Panepinto, Julie A.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The completion of the Multicenter Silent Infarct Transfusion Trial demonstrated that children with pre-existing silent cerebral infarct and sickle cell anemia (SCA) who received regular blood transfusion therapy had a 58% relative risk reduction of infarct recurrence when compared to observation. However, the total benefit of blood transfusion therapy, as assessed by the parents, was not measured against the burden of monthly blood transfusion therapy. In this planned ancillary study, we tested the hypothesis that a patient centered outcome, health-related quality of life (HRQL), would be greater in participants randomly assigned to the blood transfusion therapy group than the observation group. A total of 89% (175 of 196) of the randomly allocated participants had evaluable entry and exit HRQL evaluations. The increase in Change in Health, measured as the child's health being better, was significantly greater for the transfusion group than the observation group (difference estimate = -0.54, P ≤ 0.001). This study provides the first evidence that children with SCA who received regular blood transfusion therapy felt better and had better overall HRQL than those who did not receive transfusion therapy.

AB - The completion of the Multicenter Silent Infarct Transfusion Trial demonstrated that children with pre-existing silent cerebral infarct and sickle cell anemia (SCA) who received regular blood transfusion therapy had a 58% relative risk reduction of infarct recurrence when compared to observation. However, the total benefit of blood transfusion therapy, as assessed by the parents, was not measured against the burden of monthly blood transfusion therapy. In this planned ancillary study, we tested the hypothesis that a patient centered outcome, health-related quality of life (HRQL), would be greater in participants randomly assigned to the blood transfusion therapy group than the observation group. A total of 89% (175 of 196) of the randomly allocated participants had evaluable entry and exit HRQL evaluations. The increase in Change in Health, measured as the child's health being better, was significantly greater for the transfusion group than the observation group (difference estimate = -0.54, P ≤ 0.001). This study provides the first evidence that children with SCA who received regular blood transfusion therapy felt better and had better overall HRQL than those who did not receive transfusion therapy.

UR - http://www.scopus.com/inward/record.url?scp=84921418905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921418905&partnerID=8YFLogxK

U2 - 10.1002/ajh.23877

DO - 10.1002/ajh.23877

M3 - Article

C2 - 25345798

AN - SCOPUS:84921418905

VL - 90

SP - 139

EP - 143

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -